<p>纽约，纽约 --（Newsfile Corp. -2025 年 8 月 11 日）- 如果您在 <strong>诺和诺德公司</strong> 的投资中遭受损失，并希望了解根据联邦证券法的潜在赔偿，请点击以下链接获取更多信息：</p>
<p>https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form-3?prid=160780&amp;wire=5&amp;utm_campaign=22</p>
<p>或通过电子邮件联系 Joseph E. Levi 律师，邮箱为 jlevi@levikorsinsky.com，或拨打（212）363-7500 与我们经验丰富的股东倡导团队联系。</p>
<p><strong>诉讼：</strong> 针对诺和诺德公司提起了一项集体诉讼，旨在为在 2025 年 5 月 7 日至 2025 年 7 月 28 日期间受到证券欺诈影响的股东追回损失。</p>
<p><strong>案件详情：</strong> 根据投诉，被告向投资者提供了极为积极的声明，同时传播了实质性虚假和误导性陈述和/或隐瞒了有关诺和诺德增长潜力真实状况的重大不利事实；特别是，其声称的利用复合市场的潜力大大低估了个性化例外对复合 GLP-1 排除的潜在影响，并高估了这些患者转向诺和诺德品牌替代品的可能性，进一步高估了潜在的 GLP-1 市场或诺和诺德进入这些市场以实现持续增长的能力。</p>
<p>2025 年 7 月 29 日，诺和诺德宣布在报告 2025 财年第二季度业绩之前下调销售和利润预期。公司将下调指导归因于&#34;对 2025 年下半年 Wegovy 和 Ozempic 的增长预期降低&#34;，原因是&#34;复合 GLP-1 的持续使用、市场扩展慢于预期和竞争。&#34;</p>
<p>在此消息发布后，诺和诺德的普通股价格大幅下跌。从 2025 年 7 月 28 日的收盘市场价格每股 69.00 美元，诺和诺德的股价在 2025 年 7 月 29 日跌至每股 53.94 美元，单日下降约 21.83%。</p>
<p><strong>接下来会怎样？</strong> 如果您在相关时间段内在诺和诺德股票中遭受损失——即使您仍持有股票——请访问 https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form-3?prid=160780&amp;wire=5&amp;utm_campaign=22 了解您寻求赔偿的权利。<strong>参与没有费用或义务。</strong></p>
<p><strong>为什么选择 Levi &amp; Korsinsky：</strong> 在过去 20 年中，Levi &amp; Korsinsky LLP 已建立为一家全国知名的证券诉讼公司，为受害股东争取了数亿美元，并在高风险案件中赢得了良好的记录。该公司在复杂证券诉讼方面拥有丰富的经验，并拥有超过 70 名员工为客户服务。连续七年，Levi &amp; Korsinsky 在 ISS 证券集体诉讼服务的前 50 名报告中被评为美国顶级证券诉讼公司之一。律师广告。以往的结果并不保证类似的结果。</p>
<p><strong>联系方式：</strong></p>
<p>Levi &amp; Korsinsky, LLP</p>
<p>Joseph E. Levi, Esq.</p>
<p>Ed Korsinsky, Esq.</p>
<p>33 Whitehall Street, 17th Floor</p>
<p>纽约，NY 10004</p>
<p>jlevi@levikorsinsky.com</p>
<p>电话：（212）363-7500</p>
<p>传真：（212）363-7171</p>
<p>https://zlk.com/</p>
<p>要查看本新闻稿的源版本，请访问 https://www.newsfilecorp.com/release/261999</p>

诺和诺德公司

<p>针对诺和诺德公司（Novo Nordisk A/S）提起了一项集体诉讼，指控其在 2025 年 5 月 7 日至 2025 年 7 月 28 日期间对股东进行证券欺诈。诉讼称，该公司误导投资者关于其增长潜力的信息，导致在 2025 年 7 月 29 日宣布负面销售前景后，股价大幅下跌约 21.83%。遭受损失的股东被鼓励在 2025 年 9 月 30 日之前联系 Levi & Korsinsky LLP，以寻求潜在的赔偿选项</p>

<p>New York, New York--(Newsfile Corp. - August 11, 2025) - If you suffered a loss on your <strong>Novo Nordisk A/S</strong> investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:</p>
<div class="lb-trans"><p>纽约，纽约 --（Newsfile Corp. -2025 年 8 月 11 日）- 如果您在 <strong>诺和诺德公司</strong> 的投资中遭受损失，并希望了解根据联邦证券法的潜在赔偿，请点击以下链接获取更多信息：</p>
</div><p>https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form-3?prid=160780&amp;wire=5&amp;utm_campaign=22</p>
<div class="lb-trans"><p>https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form-3?prid=160780&amp;wire=5&amp;utm_campaign=22</p>
</div><p>or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates.</p>
<div class="lb-trans"><p>或通过电子邮件联系 Joseph E. Levi 律师，邮箱为 jlevi@levikorsinsky.com，或拨打（212）363-7500 与我们经验丰富的股东倡导团队联系。</p>
</div><p><strong>THE LAWSUIT:</strong> A class action securities lawsuit was filed against Novo Nordisk A/S that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between May 7, 2025 and July 28, 2025.</p>
<div class="lb-trans"><p><strong>诉讼：</strong> 针对诺和诺德公司提起了一项集体诉讼，旨在为在 2025 年 5 月 7 日至 2025 年 7 月 28 日期间受到证券欺诈影响的股东追回损失。</p>
</div><p><strong>CASE DETAILS:</strong> According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Novo's growth potential; notably, that its asserted potential to capitalize on the compounded market greatly understated the potential impact of the personalization exception to the compounded GLP-1 exclusion and overstated the likelihood such patients would switch to Novo's branded alternatives, and further greatly overstated the potential GLP-1 market or otherwise Novo's capability to penetrate said markets to achieve continued growth.</p>
<div class="lb-trans"><p><strong>案件详情：</strong> 根据投诉，被告向投资者提供了极为积极的声明，同时传播了实质性虚假和误导性陈述和/或隐瞒了有关诺和诺德增长潜力真实状况的重大不利事实；特别是，其声称的利用复合市场的潜力大大低估了个性化例外对复合 GLP-1 排除的潜在影响，并高估了这些患者转向诺和诺德品牌替代品的可能性，进一步高估了潜在的 GLP-1 市场或诺和诺德进入这些市场以实现持续增长的能力。</p>
</div><p>On July 29, 2025, Novo announced it was lowering its sales and profit outlook ahead of reporting its results for the second quarter of fiscal year 2025. The Company attributed the guide down on &#34;lowered growth expectations for the second half of 2025&#34; for both Wegovy and Ozempic due to &#34;the persistent use of compounded GLP-1s, slower-than-expected market expansion and competition.&#34;</p>
<div class="lb-trans"><p>2025 年 7 月 29 日，诺和诺德宣布在报告 2025 财年第二季度业绩之前下调销售和利润预期。公司将下调指导归因于&#34;对 2025 年下半年 Wegovy 和 Ozempic 的增长预期降低&#34;，原因是&#34;复合 GLP-1 的持续使用、市场扩展慢于预期和竞争。&#34;</p>
</div><p>Following this news, the price of Novo's common stock declined dramatically. From a closing market price of $69.00 per share on July 28, 2025, Novo's stock price fell to $53.94 per share on July 29, 2025, a decline of about 21.83% in the span of just a single day.</p>
<div class="lb-trans"><p>在此消息发布后，诺和诺德的普通股价格大幅下跌。从 2025 年 7 月 28 日的收盘市场价格每股 69.00 美元，诺和诺德的股价在 2025 年 7 月 29 日跌至每股 53.94 美元，单日下降约 21.83%。</p>
</div><p><strong>WHAT'S NEXT?</strong> If you suffered a loss in Novo stock during the relevant time frame - even if you still hold your shares - go to https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form-3?prid=160780&amp;wire=5&amp;utm_campaign=22 to learn about your rights to seek a recovery. <strong>There is no cost or obligation to participate.</strong></p>
<div class="lb-trans"><p><strong>接下来会怎样？</strong> 如果您在相关时间段内在诺和诺德股票中遭受损失——即使您仍持有股票——请访问 https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form-3?prid=160780&amp;wire=5&amp;utm_campaign=22 了解您寻求赔偿的权利。<strong>参与没有费用或义务。</strong></p>
</div><p><strong>WHY LEVI &amp; KORSINSKY:</strong> Over the past 20 years, Levi &amp; Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi &amp; Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.</p>
<div class="lb-trans"><p><strong>为什么选择 Levi &amp; Korsinsky：</strong> 在过去 20 年中，Levi &amp; Korsinsky LLP 已建立为一家全国知名的证券诉讼公司，为受害股东争取了数亿美元，并在高风险案件中赢得了良好的记录。该公司在复杂证券诉讼方面拥有丰富的经验，并拥有超过 70 名员工为客户服务。连续七年，Levi &amp; Korsinsky 在 ISS 证券集体诉讼服务的前 50 名报告中被评为美国顶级证券诉讼公司之一。律师广告。以往的结果并不保证类似的结果。</p>
</div><p><strong>CONTACT:</strong></p>
<div class="lb-trans"><p><strong>联系方式：</strong></p>
</div><p>Levi &amp; Korsinsky, LLP</p>
<div class="lb-trans"><p>Levi &amp; Korsinsky, LLP</p>
</div><p>Joseph E. Levi, Esq.</p>
<div class="lb-trans"><p>Joseph E. Levi, Esq.</p>
</div><p>Ed Korsinsky, Esq.</p>
<div class="lb-trans"><p>Ed Korsinsky, Esq.</p>
</div><p>33 Whitehall Street, 17th Floor</p>
<div class="lb-trans"><p>33 Whitehall Street, 17th Floor</p>
</div><p>New York, NY 10004</p>
<div class="lb-trans"><p>纽约，NY 10004</p>
</div><p>jlevi@levikorsinsky.com</p>
<div class="lb-trans"><p>jlevi@levikorsinsky.com</p>
</div><p>Tel: (212) 363-7500</p>
<div class="lb-trans"><p>电话：（212）363-7500</p>
</div><p>Fax: (212) 363-7171</p>
<div class="lb-trans"><p>传真：（212）363-7171</p>
</div><p>https://zlk.com/</p>
<div class="lb-trans"><p>https://zlk.com/</p>
</div><p>To view the source version of this press release, please visit https://www.newsfilecorp.com/release/261999</p>
<div class="lb-trans"><p>要查看本新闻稿的源版本，请访问 https://www.newsfilecorp.com/release/261999</p>
</div>

在诺和诺德公司（NVO）上亏损的投资者被敦促在2025年9月30日前加入集体诉讼 - 请联系 Levi & Korsinsky